Division Highlights - Pulmonology & Cystic Fibrosis
The Division of Pediatric Pulmonology provides family-centered care for children with respiratory disorders, including asthma, cystic fibrosis, and chronic lung disease.
Research efforts aim to improve the health of children with lung diseases.
- Philip Farrell, MD, PhD, received an American Recovery and Reinvestment (ARR) supplement of $99,810 from the NIH. He also was awarded the Wisconsin Medical Society’s Presidential Citation for his significant contributions to medicine or public health.
- Theresa Guilbert, MD, received the Wisconsin Women’s Health Foundation’s Champion in Women’s Health award for Excellence in Research and Policy in alcohol and tobacco cessation. She also received a two-year, $100,000 grant from the Wisconsin Partnership Program for her project, “Clinical and Public Health Data Exchange: Estimating Asthma Prevalence in Wisconsin.”
- Mary Schroth, MD, received a five-year renewal of her Maternal and Child Health Bureau-funded Pediatric Pulmonary Center (PPC) grant. The grant supports multidisciplinary care teams for children with complex pulmonology disorders, and provides funding for trainees in medicine, nutrition, social work, nursing, and respiratory therapy. The University of Wisconsin-Madison PPC is one of only six in the nation, and the only one in the Midwest.
Professor and Division Chief
Groose MK, Reynolds R, Li Z, Farrell PM. Opportunities for quality improvement in cystic fibrosis newborn screening. J Cyst Fibros. 2010 Jul;9(4):284-7.
Hayes D Jr, West SE, Rock MJ, Li Z, Splaingard ML, Farrell PM. Pseudomonas aeruginosa in children with cystic fibrosis diagnosed through newborn screening: assessment of clinic exposures and microbial genotypes. Pediatr Pulmonol. 2010 Jul;45(7):708-16.
Tluczek A, Becker T, Laxova A, Grieve A, Racine CN, Rock MJ, Gershan WM, Green CG, Farrell PM. Relationships among health-related quality of life, pulmonary health, and newborn screening for cystic fibrosis. Chest. 2010 Nov 24.
Guilbert T, Gern JE, Lemanske RF Jr. Infections and Asthma. In: Leung DYM, Sampson HA, Geha RS, Szefler SJ, eds. Pediatric Allergy: Principles and Practice. St. Louis: Mosby, Inc. 2010; 363-376.
Guilbert TW, Denlinger LC. Role of infection in the development and exacerbation of asthma. Expert Rev Respir Med. 2010 Feb;4(1):71-83.
Guilbert TW, Garris C, Jhingran P, Bonafede M, Tomaszewski KJ, Bonus T, Hahn RM, Schatz M. Asthma that is not well-controlled is associated with increased healthcare utilization and decreased quality of life. J Asthma. 2010 Dec 6.
Guilbert TW. Identifying and managing the infant and toddler at risk for asthma. J Allergy Clin Immunol. 2010 Aug;126(2):417-22.
Lemanske RF Jr, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, Covar RA, Guilbert TW, Larsen G, Morgan WJ, Moss MH, Spahn JD, Taussig LM; Childhood Asthma Research and Education (CARE) Network of the National Heart, Lung, and Blood Institute. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010 Mar 18;362(11):975-85.
Rock MJ, Sharp JK. Cystic fibrosis and crms screening: what the primary care pediatrician should know. Pediatr Ann. 2010 Dec;39(12):759-68.
Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010 Sep 1;182(5):627-32.
Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH. Pulmonary exacerbations are associated with subsequent FEV(1) decline in both adults and children with cystic fibrosis. Pediatr Pulmonol. 2010 Oct 21.
Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol. 2010 Feb;45(2):127-34.
Danov Z, Schroth MK. Respiratory management of pediatric patients with neuromuscular disease. Pediatr Ann. 2010 Dec;39(12):769-76.
Lewelt A, Krosschell KJ, Scott C, Sakonju A, Kissel JT, Crawford TO, Acsadi G, D'anjou G, Elsheikh B, Reyna SP, Schroth MK, Maczulski JA, Stoddard GJ, Elovic E, Swoboda KJ. Compound muscle action potential and motor function in children with spinal muscular atrophy. Muscle Nerve. 2010 Nov;42(5):703-8.
Swoboda KJ, Scott CB, Crawford TO, Simard LR, Reyna SP, Krosschell KJ, Acsadi G, Elsheik B, Schroth MK, D'Anjou G, LaSalle B, Prior TW, Sorenson SL, Maczulski JA, Bromberg MB, Chan GM, Kissel JT; Project Cure Spinal Muscular Atrophy Investigators Network. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One. 2010 Aug 19;5(8):e12140.
|Principal Investigator||Funding Agency||Title|
|Farrell, Philip||DHHS, PHS, National Institutes of Health||Pulmonary Benefits of Cystic Fibrosis Neonatal Screening|
|Farrell, Philip||Cystic Fibrosis Foundation||Pulmonary Benefits of Cystic Fibrosis Neonatal Screening|
|Farrell, Philip||Medical College of Wisconsin||A Rapid-Throughput Feedback Intervention for Population-State Communication Quality Assurance Projects|
|Rock, Michael||Inspire Pharmaceuticals, Inc.||A Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Efficacy and Safety Study of Denufosol Tetrasodium|
|Rock, Michael||Inspire Pharmaceuticals, Inc.||Study 08-114: Open-Label Extension of Study 08-110 -- A Multi-Center Study of Denufosol Tetrasodiom Inhalation Solution in Patients with Cystic Fibrosis Lung Disease|
|Rock, Michael||Inspire Pharmaceuticals, Inc.||A Phase 3, Efficacy and Safety Study of Denufosol Tetrasodium Inhalation Solution in Patients with Cystic Fibrosis Lung Disease and FECI >= 75% Predicted|
|Rock, Michael||Seattle Children's Hospital and Regional Medical Center||EPIC-002: Schedule 3.0 The Epic Observational Study — Longitudinal Assessment of Risk Factors for and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with Cystic Fibrosis|
|Rock, Michael||Seattle Children's Hospital and Regional Medical Center||EPIC-001: Efficacy and Safety of Intermittent Antimcrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients with Cystic Fibrosis|
|Rock, Michael||University Of North Carolina - Chapel Hill||Infant Study of Inhaled Saline (ISIS)|
|Rock, Michael||Cystic Fibrosis Foundation Therapeutics||Cystic Fibrosis Therapeutic Network|
|Rock, Michael||Axcan Pharma||Efficacy and Safety of Ultrase MT12 in the Control of Steatorrhea in Cystic Fibrosis and Pancreatic Insufficient Children Aged 2-6 Years Old|
|Rock, Michael||Cystic Fibrosis Foundation||Cystic Fibrosis Center Grant|
|Rock, Michael||Wisconsin Department of Health Services||Congenital Disorders Program|
|Rock, Michael||Cystic Fibrosis Foundation||Cystic Fibrosis Clinical Research Fellowship|
|Schroth, Mary||Families of Spinal Muscular Atrophy||Phase I/II Trial of Valproic Acid and Carnitine in Infants with Spinal Muscular Atrophy Type I (CARNI-VAL Type I)|
|Schroth, Mary||DHHS, PHS, Health Resources and Services||Pediatrics Pulmonary Center|
|Schroth, Mary||Respironics||Engineering Evaluation of Enhanced Leak Detection for Non-Invasive Ventilation in Pediatrics|